Corrigendum to the Annual Report for the Financial Year 2024-25
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals has issued a corrigendum to its FY 2024-25 Annual Report that was originally sent on September 1, 2025. The company identified an inadvertent oversight where Annexure 1 and 2 to the Independent Auditor's Report were missed out and have now been inserted after page 109. The 46th AGM is scheduled for September 24, 2025 at 3:30 PM via video conferencing. The updated annual report has been filed with BSE and NSE and is also available on the company's website. Key financial highlights from the attached annual report include: Revenue of ₹2,687 million (up 28.8% YoY), Operating EBITDA of ₹579 million (up 59.1%) with margin at 21.5%, and Operational PAT of ₹375 million (up 66.9%). The company reported strong cash position of ₹1,456 million despite funding the Yash Pharma acquisition (~₹950 million) from internal accruals. The board proposed a dividend of 125% (₹2.50 per share).
This is a routine procedural correction to fix an oversight in the statutory annual report disclosure and is unlikely to materially affect shareholders or stock price. However, the underlying annual report reflects strong FY25 performance with significant revenue growth, margin expansion, and a healthy balance sheet supporting future inorganic growth.